Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Osimertinib activates a TGF-β2–dependent secretory program that drives lung adenocarcinoma progression
Madhurima Ghosh, Chao Wu, Abhishek Kumar, Monique Nilsson, John V. Heymach, Weina Zhao, Jiang Yu, Xin Liu, Na Ding, Shike Wang, Guan-Yu Xiao, Angelo Chen, Kate Grimley, William K. Russell, Chad J. Creighton, Xiaochao Tan, Jonathan M. Kurie
Madhurima Ghosh, Chao Wu, Abhishek Kumar, Monique Nilsson, John V. Heymach, Weina Zhao, Jiang Yu, Xin Liu, Na Ding, Shike Wang, Guan-Yu Xiao, Angelo Chen, Kate Grimley, William K. Russell, Chad J. Creighton, Xiaochao Tan, Jonathan M. Kurie
View: Text | PDF
Research Article Cell biology Clinical Research Oncology

Osimertinib activates a TGF-β2–dependent secretory program that drives lung adenocarcinoma progression

  • Text
  • PDF
Abstract

EGFR-mutant lung adenocarcinomas (LUADs) that are vulnerable to the EGFR antagonist osimertinib (Osi) eventually relapse, owing in part to the emergence of drug-tolerant persister (DTP) cells that arise through epigenetic mechanisms. Intratumoral DTP cells can herald a worse clinical outcome, but the way in which DTP cells influence LUAD progression remains unclear. Osi-resistant (OR) cells exhibit typical DTP cell features, including a propensity to undergo senescence and epithelial-mesenchymal transition (EMT), which can activate heightened secretory states. Therefore, we postulated that OR cells influence LUAD progression through paracrine mechanisms. To test this hypothesis, we utilized congenic pairs of EGFR-mutant LUAD cell lines in which drug-naive (DN) cells were rendered OR by chronic exposure to escalating doses of Osi. Cocultured in vitro or coinjected into mice, paracrine signals from OR cells enhanced the growth and metastatic properties of DN cells. EMT and senescence activated nonoverlapping secretomes, and OR cells governed DN cells by undergoing EMT but not senescence. Mechanistically, Osi rapidly increased TGF-β2 levels to initiate EMT, which triggered a Golgi remodeling process that accelerated the biogenesis and anterograde trafficking of secretory vesicles. The protumorigenic activity of OR cells was diminished by depletion of EMT-dependent secreted proteins or the EMT-activating transcription factor ZEB1. These findings identify paracrine mechanisms by which OR cells drive LUAD progression.

Authors

Madhurima Ghosh, Chao Wu, Abhishek Kumar, Monique Nilsson, John V. Heymach, Weina Zhao, Jiang Yu, Xin Liu, Na Ding, Shike Wang, Guan-Yu Xiao, Angelo Chen, Kate Grimley, William K. Russell, Chad J. Creighton, Xiaochao Tan, Jonathan M. Kurie

×

Figure 4

Identification of secretory mediators in H1975 OR cells.

Options: View larger image (or click on image) Download as PowerPoint
Identification of secretory mediators in H1975 OR cells.
(A) Volcano plo...
(A) Volcano plot of proteins identified by LC-MS analysis of CM samples isolated from H1975 cells (DN or OR). Proteins (dots) plotted by P value (y axis) and fold change (x axis). Fold change > 2, P < 0.05. Proteins of interest are labeled. (B and C) WB analysis of secreted proteins of interest in whole-cell lysate (WCL) and CM samples from H1975 cells (DN or OR) (B) or HCC827 cells (DN or OR) (C). β-Actin served as loading control. (D) WB confirmation of target gene depletion (CEMIP, COL6A1, or L1CAM) in siRNA-transfected HCC827 cells. siCtrl, control. β-Actin served as loading control. (E) Relative densities of siRNA-transfected HCC827 OR cells following 4 days of Osi treatment in monolayer culture. IC50 values were calculated. (F) Boyden chamber migration assays on siRNA-transfected cells. Results expressed relative to siCtrl. (G) Relative densities of siRNA-transfected HCC827 cells in monolayer culture quantified on day 4. (H) WB analysis of L1CAM and COL6A1 in CM and WCL samples following treatment with brefeldin A (10 μg/mL) for 4 hours in H1975 DN and OR cells. (I) WB analysis of L1CAM in CM samples from H1975 OR cells after 24-hour treatment with 1 μM Ruxo. p-STAT3 levels in WCL included as positive control for drug target inhibition. Data are the mean ± SD from a single experiment incorporating biological replicate samples (n = 3, unless otherwise indicated) and are representative of at least 2 independent experiments. Two-way ANOVA with Dunnet’s post hoc test (E). One-way ANOVA with Dunnet’s post hoc test (F and G). ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts